Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview

Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design

(2016) Xuefeng Cao et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective

(2016) Tushar Madaan et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models

(2016) Manthena V. Varma et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2014) Lingyu Zhang et al.   Medicinal Chemistry

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy

N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

(2013) Yasuo Yamamoto et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

(2013) Anita Kapur et al.   BMC Pharmacology & Toxicology

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

(2013) Elizabeth K Hussey et al.   BMC Pharmacology & Toxicology

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

(2012) Yoshihito Ohtake et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Regional gastrointestinal delivery of remogliflozin etabonate in humans

(2012) Robin L. O'Connor-Semmes et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

(2011) R. L. Dobbins et al.   DIABETES OBESITY & METABOLISM

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

(2011) A. S. Kalgutkar et al.   DRUG METABOLISM AND DISPOSITION

Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors

(2011) Vincent Mascitti et al.   JOURNAL OF MEDICINAL CHEMISTRY

Potential drug interactions associated with treatments for Type 2 diabetes and its comorbidities: a clinical pharmacology review

(2011) Jeffrey S Freeman et al.   Expert Review of Clinical Pharmacology

Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment

(2010) D. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study

(2010) Elizabeth K. Hussey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Single-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

(2010) Elizabeth K. Hussey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Influence of SLCO1B3 Gene Polymorphism on the Pharmacokinetics of Digoxin in Terminal Renal Failure

(2009) Masayuki Tsujimoto et al.   Drug Metabolism and Pharmacokinetics

Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

(2008) Pertti J Neuvonen et al.   CLINICAL PHARMACOKINETICS

Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

(2008) IS Song et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION